Lloyd Payne

Lloyd Payne serves as the CEO of AMR NewCo, leading initiatives in antibacterial drug discovery and developing broad-spectrum antibacterials for drug-resistant infections. With an extensive background in infectious disease research, Lloyd holds key advisory roles at the AMR Action Fund, Centauri Therapeutics, and the Novo REPAIR Impact Fund. Previous leadership includes the position of CEO at ArrePath, a biotech firm focused on anti-infective development, and involvement with various organizations such as the Infection Innovation Consortium and Perfectus Biomed Group. Lloyd's academic foundation includes a PhD in Synthetic Organic Chemistry from the University of Sussex.